BPA
SMMT icon

Beacon Pointe Advisors’s Summit Therapeutics SMMT Stock Holding History

Beacon Pointe Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
98,114
+3,720
+4% +$66K 0.01% 894
2026
Q1 		$1.79M Buy
94,394
+54,783
+138% +$886K 0.01% 771
2025
Q4 		$693K Buy
39,611
+3,885
+11% +$73.1K ﹤0.01% 953
2025
Q3 		$738K Buy
+35,726
New +$866K 0.01% 872

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Beacon Pointe Advisors's SMMT Position: Q2 2026 in Review

Beacon Pointe Advisors increased its Summit Therapeutics (SMMT) stake by 3.9% in Q2 2026, buying an estimated $66K and bringing the position to 98,114 shares worth $1.43M. The position accounts for 0.01% of the portfolio, ranked #894.

Beacon Pointe Advisors first reported a position in SMMT in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.79M in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Beacon Pointe Advisors held 98,114 shares of Summit Therapeutics worth $1.43M as of Q2 2026.
  • Beacon Pointe Advisors bought 3,720 Summit Therapeutics shares in Q2 2026, an estimated $66K.
  • Summit Therapeutics made up 0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #894 holding.
  • Beacon Pointe Advisors first reported a position in Summit Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Beacon Pointe Advisors's Summit Therapeutics position peaked at $1.79M in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.